Doctoral School, Victor Babes University of Medicine and Pharmacy, 300041 Timisoara, Romania.
Discipline of Sociobiology, Department of Ethics and Social Sciences, George Emil Palade University of Medicine, Pharmacy, Science and Technology of Targu Mures, 540136 Targu Mures, Romania.
Int J Mol Sci. 2024 Jul 20;25(14):7937. doi: 10.3390/ijms25147937.
The gut microbiota has acquired significant attention in recent years for its potential as a diagnostic biomarker for colorectal cancer (CRC). In this literature review, we looked at the studies exploring alterations in gut microbiota composition associated with CRC, the potential mechanisms linking gut dysbiosis to CRC development, and the diagnostic approaches utilizing gut microbiota analysis. Our research has led to the conclusion that individuals with CRC often display alterations in their gut microbiota composition compared to healthy individuals. These alterations can include changes in the diversity, abundance, and type of bacteria present in the gut. While the use of gut microbiota as a diagnostic biomarker for CRC holds promise, further research is needed to validate its effectiveness and standardize testing protocols. Additionally, considerations such as variability in the microbiota composition among individuals and potential factors must be addressed before microbiota-based tests can be widely implemented in clinical practice.
近年来，肠道微生物群因其作为结直肠癌 (CRC) 诊断生物标志物的潜力而受到极大关注。在本次文献综述中，我们研究了探索与 CRC 相关的肠道微生物群组成变化、肠道失调与 CRC 发展之间潜在联系的机制，以及利用肠道微生物群分析的诊断方法。我们的研究得出的结论是，与健康个体相比，CRC 患者的肠道微生物群组成通常会发生改变。这些变化可能包括肠道中存在的细菌的多样性、丰度和类型的变化。虽然肠道微生物群作为 CRC 的诊断生物标志物具有很大的应用前景，但需要进一步的研究来验证其有效性并标准化检测方案。此外，在广泛应用基于微生物群的检测方法之前，还必须考虑个体间微生物群组成的可变性以及潜在的因素。
